Insperity earnings and guidance draw investor focus

Insperity (NSP) is in the spotlight after reporting second quarter 2026 results that moved from a net loss to a net profit, alongside fresh earnings guidance for the third quarter and full year.

Following the earnings release and updated guidance, Insperity's recent share price moves have been volatile, with the share price down 2.48% over the last day and 4.49% over the past week, yet up 12.55% over 30 days and 62.24% over 90 days. That contrasts with a 10.62% total shareholder return over 1 year and double digit declines on a 3 and 5 year total shareholder return basis, suggesting short term momentum has picked up while longer term holders have experienced weaker results.

If you are reassessing Insperity after this earnings update, it can be useful to compare it with other opportunities that have different growth and risk profiles through the 19 top founder-led companies

After a sharp rebound in Insperity's share price, the stock now sits only a touch below the average analyst target, while some intrinsic value estimates suggest a much wider gap. Which reference point looks closer to fair value?

Most Popular Narrative: 17.1% Overvalued

Insperity's most followed narrative points to a fair value of $43.75 per share compared with the latest close at $51.22. As a result, the narrative sees expectations as stretched and heavily dependent on future execution.

The upcoming launch of Insperity HRScale, a joint solution with Workday, targets a broader and more lucrative mid-market segment by leveraging both advanced HR technology and comprehensive services. This is expected to support higher revenue growth and improved operating leverage as premium pricing and larger average client size become possible.

Want to see what revenue path, margin rebuild and future profit multiple have to look like for that target to add up? The full narrative lays out a detailed earnings roadmap and a valuation bridge that leans heavily on those long term assumptions.

Result: Fair Value of $43.75 (OVERVALUED)

However, Insperity's reliance on smaller businesses and its concentration with UnitedHealthcare mean weaker client hiring or renewed healthcare cost pressure could quickly challenge this overvaluation narrative.

Another view on Insperity valuation

The narrative around Insperity leans on a fair value of $43.75, which suggests the current $51.22 share price looks stretched. Yet on simple sales-based metrics, Insperity trades at a P/S of 0.3x compared with an industry average and peer average of 0.9x and a fair ratio of 0.7x. That points to a stock the market prices more cheaply per dollar of revenue, even after the recent rebound. This raises the question of whether expectations or the multiple eventually move first for investors weighing the risk-reward trade-off.

Next Steps

With sentiment on Insperity looking mixed between risks and rewards, now is a good time to review the details yourself and decide how the story stacks up. To see both sides in one place, check out the 3 key rewards and 1 important warning sign

Looking for more investment ideas beyond Insperity?

If Insperity's story has you thinking about your wider portfolio, now is the moment to line up a few fresh ideas before the next move catches you off guard.

• Strengthen your income stream by reviewing companies that appear built for consistent payouts through the 9 dividend fortresses.
• Focus on potential value candidates that combine quality fundamentals with appealing pricing using the 51 high quality undervalued stocks.
• Work to reduce portfolio shocks by concentrating on businesses with steadier profiles through the 83 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.